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Advances in genomic technologies and a growing trend towards stratiﬁed and
preventive approaches to medicine mean that increasing numbers of individuals
may have access to information about their genetic makeup, and their risk of
developing diseases. This is likely to impact on healthcare professionals involved
in the delivery of genetic tests, or in supporting patients who are affected by a
disease with a genetic risk factor. It is therefore important to understand health-
care professionals’ perceptions about providing these services, and how they feel
about communicating information about genetic risk to patients. This paper pro-
vides a systematic review and metasynthesis of qualitative research exploring
healthcare professionals’ perceptions of genetic risk in the context of predictive
genetic testing for chronic disease. Healthcare professionals expressed a range of
reservations about the utility of predictive testing in this context. Professionals
judged patients’ understanding of risk information to be limited and subject to
bias and a range of sociocultural inﬂuences. Concerns about the psychosocial
impact of genetic risk information were frequently cited, both in relation to indi-
vidual patients and the wider impact on their families and communities. The
need for provision of multidisciplinary support was described. The concept of
responsibility was also an important theme. Healthcare professionals recognized
the responsibility that accompanies risk knowledge, and that ultimately this
responsibility lies with the patient, not the provider. Our analysis suggests that
professionals’ evaluation of the utility of predictive genetic testing is inﬂuenced
not only by resource deﬁcits, but may also be interpreted as a response to chal-
lenging ethical and social issues associated with genetic risk, that are not well
aligned with current medical practice.
Keywords: healthcare professionals; perceptions; genetic risk; qualitative;
review
Introduction
The rapid expansion of genomic technologies has created promising opportunities
for personalized approaches to health care. The identiﬁcation of genetic variants that
inﬂuence susceptibility to and outcome of disease facilitates preventive and stratiﬁed
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therapeutic interventions. Consequently, the demand for and availability of genetic
tests to predict the development of diseases with a heritable component are increas-
ing (Guttmacher et al. 2010).
Genetic testing has traditionally been available in medical settings, and delivered
by specialist professionals in the context of monogenic diseases. As genomic medi-
cine advances and is increasingly applied to the prevention and treatment of com-
mon disorders with complex genetic and environmental aetiologies (Sparks et al.
2014; Wilson and Nicholls 2015), it is likely that a wider range of non-specialist
health care professionals (HCPs) will become more involved in the delivery of
genetic services. Therefore, it is increasingly important that HCPs develop a thor-
ough understanding of medical genetics (Feero and Green 2011), and are equipped
to communicate complex risk information in a way that is disease appropriate, and
that takes into consideration the values and needs of patients (Lautenbach et al.
2013).
The availability of genetic testing is no longer restricted to health care settings.
Genetic information is available to individuals via a wide range of home testing kits
available directly to consumers (DTC) from private companies (Frueh et al. 2011).
Public awareness and demand for such testing have grown (Su 2013; Agurs-Collins
et al. 2015), though this market is facing increased regulation (Kalokairinou,
Howard, and Borry 2014). As consumers become more aware of genetics, and have
increased access to genetic data, it is likely that they will want to discuss issues sur-
rounding genetic testing with HCPs. An internet-based survey by McGuire et al.
(2009) found that 78% of those respondents who would consider using DTC testing
would ask their physician to help them interpret the results.
The clinical translation of the expansion in genomic medicine is still at an early
stage (Vassy, Green, and Lehmann 2013), and there are considerable gaps in our
knowledge about the organizational requirements and clinician and patient needs
(Scheuner, Sieverding, and Shekelle 2008). In order to support the integration of this
knowledge into clinical practice, it is important to understand HCPs’ willingness to
engage with the delivery of genetic services. A systematic review by Emery et al.
(1999) speciﬁcally explored the views of General Practitioners (GPs) about clinical
genetics and the role of primary care in the delivery of genetic services. The review
found that whilst GPs accepted their increasing role, they lacked conﬁdence in their
ability to deliver genetic services because of lack of knowledge of clinical genetics.
These ﬁndings were echoed in a review by Suther and Goodson in 2003 of per-
ceived barriers to the integration of genetics into primary care practice. Barriers
included inadequate knowledge, inadequate family history gathering, lack of conﬁ-
dence and a lack of referral guidelines.
More than a decade later, a recent review by Mikat-Stevens, Larson, and Tarini
(2015) produced similar ﬁndings. Primary care providers frequently mentioned lack
of knowledge about genetics and genetic risk assessment, concern for patient anxi-
ety, lack of access to genetics and a lack of time as important barriers to the integra-
tion of genetic medicine into routine patient care.
The existing reviews described above (Emery et al. 1999; Suther and Goodson
2003; Mikat-Stevens, Larson, and Tarini 2015) have focused on the views of pri-
mary care providers, though a wider range of professionals, including non-genetic
specialists from medical and other HCP backgrounds, are likely to be increasingly
involved in clinical genetics in many areas of medicine. The reviews included stud-
ies of a wide range of very different (and sometimes unspeciﬁed) kinds of genetic
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testing. The context in which genetic testing occurs has an important bearing on the
full meaning and impact of the test results, both for providers and patients. For
example, the issues raised by a prenatal genetic test with consequences for reproduc-
tive decision-making are different from those associated with testing in a pharmaco-
genetic context in order to identify optimum treatment strategies. Similarly, genetic
testing in paediatric settings raises different issues compared with testing adult
patients.
The previous reviews described above included both quantitative and qualitative
research, and employed evaluation criteria and review methods that favour quantita-
tive methods. However, as noted by Suther and Goodson (2003), information from a
relatively small number of qualitative studies provided richer descriptions of respon-
dents’ views. The aim of this paper is to provide a systematic review and synthesis
of the qualitative research literature focusing on perceptions of HCPs about genetic
risk pertaining to a speciﬁc context; genetic testing for the prediction of the develop-
ment of chronic somatic disease in adults. We have used metasynthesis techniques
(Downe 2008) to organize qualitative data from multiple papers into themes, and to
provide an interpretation of recurring and inter-relating themes relating to genetic
risk across studies.
Methods
Study selection criteria
Research publications meeting the following criteria were included in this review:
(1) Primary research using qualitative research methods to explore the views of
participants, with qualitative ﬁndings (quotations) reported (allowing for ﬁrst
order analysis to be undertaken).
(2) Research participants were non-student HCPs. For the purpose of this
review, a HCP is deﬁned as a person working professionally in a healthcare
setting offering informed health advice and health services to members of
the public.
(3) Research ﬁndings involve discussion of predictive genetic testing, and/or the
communication of genetic risk information for chronic, somatic diseases in
adults.
(4) Papers written in the English language.
(5) Peer-reviewed publications (excluding abstracts and theses).
Research publications meeting the following criteria were excluded from this
review:
(1) Research articles reporting qualitative methods that focus on the analysis of
interactions between HCPs, or between patients and professionals, rather
than the direct elicitation of professionals’ viewpoints.
(2) Research articles not providing identiﬁable ﬁndings that were explicitly
related to predictive testing for chronic disease in adults. Excluded papers
include those relating to genetic testing in paediatric; pharmacogenomics;
prenatal; newborn; preconception/carrier; kinship; and nutrigenomic contexts.
Articles relating to the prediction of psychiatric disorders and substance use
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disorders were also excluded as these conditions raise very speciﬁc issues
that may be distinct from those raised by other diseases.
(3) Research articles that focused on genetic testing and/or risk communication
in research settings, rather than clinical practice.
(4) Research articles that focused mainly on the perceptions of members of the
public, and little reference was made to relevant ﬁndings from HCP partici-
pants.
(5) Research articles that focused on genetic testing after the onset of symptoms
to conﬁrm a diagnosis, or post-diagnosis testing to inform treatment.
Search strategy
The following databases were searched to identify relevant articles: Ovid MEDLINE
(Pubmed; 1950 – present), CINHAL (1982 – present), PsycINFO (1967 – present),
EMBASE (1947 – present), Web of Science (1900 – present) and Health Manage-
ment Information Consortium (1979 – present). The search terms used are displayed
in Table 1.
In total, 7687 publications were initially identiﬁed and 2822 duplicate articles
were removed. The authors agreed to limit the search to research that was published
on or after the year 2000, as this represents a relevant milestone in the completion
of Human Genome Project (Collins and McKusick 2001), after which public aware-
ness of genetics increased (Tambor et al. 2002). The abstracts of all 4132 remaining
publications, and 169 full text publications, were read (by MF) in order to identify
relevant studies. A sample of 1000 abstracts were independently read and assessed
for relevance by RS. The level of agreement between researchers about relevance of
studies was very high. There was continuous analysis and reﬁnement of the applica-
tion of exclusion and inclusion criteria (listed above) amongst researchers (MF, RS,
and KR). Twenty-eight studies were selected for inclusion in the metasynthesis. The
search process is summarized in Figure 1.
Table 1. Search terms.
professional OR AND genetic OR AND qualitative OR
provider OR genom* OR theme OR
practitioner OR chromosome* OR thematic OR
personnel OR DNA OR interview OR
physician OR ‘deoxyribonucleic acid’ OR ‘focus group’ OR
Doctor OR ‘family history’ OR ‘conversation analysis’ OR
Nurse OR heredit* OR ‘discourse analysis’ OR
Specialist OR inherit* OR IPA OR
counsel* OR ‘gen* sequenc*’ OR phenomenological OR
geneticist ‘exom* sequenc*’ OR ethnograph* OR
WGS OR
WES OR
CMA OR
‘carrier test’ OR
‘incidental ﬁnding’ OR
‘unsolicited ﬁnding’
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Analysis
The application of quality criteria to qualitative research is contentious (Downe
2008; Carroll, Booth, and Lloyd-Jones 2012), and agreement between experienced
qualitative researchers using standardized checklists for the appraisal of qualitative
research can be low (Dixon-Woods et al. 2007). After careful reading of the 28 stud-
ies selected for inclusion in this metasynthesis, and discussion amongst the authors
guided by Walsh and Downe’s quality assessment tool (Walsh and Downe 2005;
Downe, Simpson, and Trafford 2007), it was agreed that all of the 28 studies con-
tained material that could usefully contribute towards the objectives of the present
analysis, and that none were so ﬂawed that the integrity and validity of the metasyn-
thesis would be compromised by their inclusion. A summary of the 28 studies,
including methodological details and reported quality assurance measures, can be
found in Table 2.
Metasynthesis is a technique for the synthesis of qualitative data and the devel-
opment of theoretical frameworks that is derived from meta-ethnographic methods
(Noblit and Hare 1988). This method has previously been used to identify core
themes in barriers to seeking help at the onset of rheumatoid arthritis, and to explore
patients’ experience of symptoms across multiple qualitative studies (Stack et al.
Records identified through 
database search
(n=7687)
Records after duplicates 
removed
(n=4865)
Records Pre-2000 
excluded
(n=733)
Abstracts from 2000 
onwards screened
(n=4132)
Full-text articles assessed 
for eligibility
(n=169)
Records excluded
(n=3963)
Studies included in meta-
synthesis
(n=28)
Full-text articles excluded
(n=141)
Figure 1. Summary of search process.
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2012, 2013). Metasynthesis has also been used to understand individuals’ perception
of disease risk (Walter, Emery, et al. 2004). Applying this approach, the studies
identiﬁed in our systematic review were analysed using thematic analysis (Braun
and Clarke 2006). All 28 studies were initially coded by MF and a sample of 7
(25%) were independently coded by RS. Coding agreement between researchers
was high. Initial ﬁrst-order coding was applied to participant quotations and to key
ﬁndings for each of the studies included. Initial codes and any discrepancies were
discussed and agreed by MF and RS, and classiﬁed into second-order thematic cate-
gories. Higher (third) order themes were then interpreted to try and integrate the sec-
ond-order themes and to describe inter-relationships amongst them. There was
continuous review and comparison of themes amongst researchers (MF, RS, and
KR) at each stage of the analysis.
Results
Of the 28 studies included in the metasynthesis, 21 explored HCPs’ perceptions of
predictive genetic testing and/or genetic risk counselling for cancer, 1 for familial
hypercholesterolemia, 1 for polycystic kidney disease, 1 for diabetes, 1 for late-onset
neurodegenerative disorders and 3 for predictive testing for more than one adult
onset disease.
Nine of the studies were conducted in the United Kingdom, 5 in the USA, 5 in
Canada, 3 in Australia, 3 in Portugal, 2 in Japan and 1 in Norway.
The main themes developed from the metasynthesis were: (1) Value of genetic
risk information; (2) Understanding of genetic risk information; (3) Consequences of
genetic risk information; and (4) Responsibility for genetic risk information. Illustra-
tive quotations for each of these themes and associated subthemes are presented
below and supplemented in Table 3 (T3; Q1–79).
Theme 1: Value of genetic risk information
This theme describes the views expressed by HCPs about the value of genetic risk
information. These views relate to the clinical utility and validity of such informa-
tion, use of genetic information in current and future practice, and to the potential of
information about genetic risk to promote healthy behavioural change by patients.
1a. Utility and validity (T3; Q1–10)
Many HCPs felt that genetic test results did not give useful information about dis-
ease risk over and above information already available to them from family history
and/or environmental risk factors (Birmingham et al. 2003; Cox and Starzomski
2004; Martin, Currie, and Finn 2009; Harvey 2011; Will, Armstrong, and Marteau
2010; Graves et al. 2011; Yamanaka and Takeda 2011; Tan and Fitzgerald 2014).
The problem with this is … how does that change what we already know from years
and years of PSA, age, family history, all the normal clinical things …? [Provider,
USA; Birmingham et al., 2003, 8]
Professionals stated that risk information from genetic tests lacked validity, and was
not yet supported by sufﬁcient evidence to be of use. The prospect of making medi-
cal decisions on the basis of information associated with a high level of uncertainty
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Table 3. Quotations to support themes and subthemes.
Theme 1. Value of genetic risk information
Subtheme 1a. Utility and validity
Q1. The problem with this is … how does that change what we already know from years
and years of PSA, age, family history, all the normal clinical things …? [Provider, USA;
Birmingham et al. 2003, 8]
Q2. There is a limitation on how useful testing is … how is this going to affect this
person’s life? Is it going to add quality of life or quantity of life? [General practitioner;
Australia; Tan and Fitzgerald 2014, 25]
Q3. Data is not compelling enough and seems more likely to lead to dilemma in
interpretation and further recommendations. [Provider, USA; Birmingham et al. 2003, 5]
Q4. If you’re going to do something which has a profound signiﬁcance, you’ve got to be
damn sure of the validity of your advice according to the results of that test. And I don’t
think we’re in that position right now. [Family physician, Canada; Carroll et al. 2003,
49]
Q5. We know it’s [genetic testing] going to improve, but it’s not here yet, and that very
ﬁrst of all it’s frustrating, and because you like to practice evidence based medicine.
[Oncologist, UK; Kenen et al. 2011, 5]
Q6. I think that quite often having the DNA test, although it can be useful and you know
in the case of a family member who wants to know are they at risk of developing high
cholesterol they may want to have the genetic test, but having said that very often there
isn’t any particular advantage over and above just keeping an eye on their cholesterol
anyway. [Consultant physician, UK; Will, Armstrong, and Marteau 2010, 913]
Q7. Because at the moment I am looking at risks anyway, just normal family history, and
if someone has a strong family history I will be emphasizing it more anyway. So yes,
that would be just another one. You know, it would just be another issue. [General
practitioner, UK; Harvey 2011, 319]
Q8. We do know that there are some families in which there is deﬁnitely a genetic
component. I think unfortunately anyway the treatment is the same, it doesn’t change
our treatment. [Diabetologist, UK; Harvey 2011, 317]
Q9. We don’t want to obsess and medicalise our patients when we have quite a lot of
suspicion that there is not going to be much that can be offered by the experts to
reassure them. [General practitioner, UK; Stermer et al. 2004, 50]
Q10. I don’t send them to a geneticist … Only if it’s a young woman who wants to have
kids and she wants to have a different kind of discussion than I give her then I’ll send
them, but otherwise not … what will they add to what I can do except freak them out?
… It’s like it sounds very scary to go to medical genetics and it’s like a genetic disease
and all of a sudden it’s got this whole other spin to it. [Nephrologist, Canada; Cox and
Starzomski 2004, 146]
Subtheme 1b. Use of genetic testing in current and future practice
Q11. The frustrating thing is all these tests become available so quickly and you’re swept
up into doing them or people are coming in and asking for certain things, and… you
don’t necessarily realize all the consequences at that point. You’re being swept along in
this wave of newer technology … It’s really overwhelming. It’s hard to know if you’re
doing good by ordering these tests. [Family physician, Canada; Carroll et al. 2003, 49]
Q12. This is the tip of the iceberg in terms of genetic testing.… As we have more genes to
screen for, it’s not going to be practical to send everyone to the genetics clinic. There’s
going to be more pressure for us to do it. … At some stage we’re going to end up
having to do it. [Family physician, Canada; Carroll et al. 2003, 48]
Q13. I think cancer genetics will, I think all predictive genetics will end up becoming part
of general health care. We have, I just counted, I think 30 clinical geneticists in Ontario.
Probably about 100 across the country. We cannot possibly see all these people. We just
can’t. So I think what has to happen is that the geneticists will end up in a consultative
(Continued)
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role and we will kind of get things going. [Clinical geneticist, Canada; Miller,
Giacomini, and Ahern 2008, 156]
Q14. Some people come and say ‘Can I be referred to ﬁnd out more?’ And that’s what
they want. So then it’s quite hard to say No. [General practitioner, UK; Al-Habsi et al.
2008, 755]
Subtheme 1c. Impact on health related behaviour
Q15. I guess Polycystic is a little different, because there are things you can do, there’s
even diet, you can take control of your diet. And there is a sense that you’re doing
something, right? [Social worker, Canada; Cox and Starzomski 2004, 145]
Q16. It might actually, if a patient sees the increased risk, increase their compliance as far
as coming in for regular exams or at least being willing to get the digital rectal exam.
[Provider, USA; Birmingham et al. 2003, 8]
Q17. You can’t get people to do some of these things [adhere to diet and exercise
recommendations] that we have known for years and have good statistical information.
We can prove it over and over again how much more beneﬁcial it would be for them
and we can’t get them to do it. You get a test like this, and I don’t know if it would help
or not. [Provider, USA; Birmingham et al. 2003, 8]
Q18. You can talk until you’re blue in the face about all these things being a good thing
but actually, these kind of health behaviors are very difﬁcult if people aren’t doing them
already and which is why the world is becoming a fatter place. Because people don’t do
the things they’re meant to be doing. So I think although I think it’s my role to promote
these things and we’ll talk about it, I feel a bit nihilistic about the fact that I don’t think
people are going to change. Most people are not going to change their behaviors.
[Medical specialist, Australia; Rees et al. 2006, 101]
Theme 2. Understanding of genetic risk information
Subtheme 2a. Assessment of understanding
Q19. Most women don’t know. They kind of come up with this statement of, ‘Okay, I
want to know if I carry the gene or not.’ They have no idea what the implications are,
what it means, what the risks are. I mean, it is sort of like a ‘yes or no’ test they are
looking for. [Physician, Canada; Bottorff et al. 2000, 1453]
Q20. And sometimes I have to sit and think about … [the results] because like you said,
just in that little discussion we had, we were all looking at it [statistical computation of
risk]and going, now wait a minute, what is this and what is this? [Provider, USA;
Birmingham et al. 2003, 7]
Q21. The most common scenario in my ofﬁce is that people come in because they have
one or two or more ﬁrst- or second-degree relatives with cancer and say, ‘What are my
chances of getting this?’ And usually I don’t know. [Family physician, Canada; Carroll
et al. 2003, 48]
Q22. I don’t think when people are thinking about their risk, they’re thinking about them
in numbers the way we are, so as geneticists, we’re thinking about your risk as 15 vs.
10%, but for the average woman, they might just be feeling like, ‘Yeah, my mom and
sister got breast cancer; it’s probably going to happen to me too’. [Genetic counsellor,
USA; Overby et al. 2013, 245]
Q23. I deﬁne genetic counselling as recognizing and exploring issues that are relevant for
a particular family member. For example, previous family history, what happened, how
that has affected the client’s view of breast cancer, what the outcomes have been for the
family, what position/age the person was when she (ﬁrst) became aware of family
history and the impact that has had on her (e.g. mother diagnosed with breast cancer
when going through adolescence). [Genetic counsellor, Australia; Lobb et al. 2001, 190]
Q24. The patients do not know the type of cancer in the family; they can be remarkably
unspeciﬁc. [General practitioner, UK; Al-Habsi et al. 2008, 755]
Q25. There are patients here I saw three years ago with nothing particular in their family
history and they present three years later with two or three family members with breast
cancer. [Nurse, Wales; Iredale et al. 2005, 201]
(Continued)
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Subtheme 2b. Determinants of understanding
Q26. I think it is important to know the personal background, where the consultands come
from, their motivations for being here, what do they already know about the illness and
the test, in order to allow us to deconstruct their beliefs, if needed. [Clinical
psychologist, Portugal; Paneque et al. 2014, 4]
Q27. You need to change your approach according to the sensibilities of your patients so
as to assure positive effects of the test results. [Diabetologist, Japan; Yamanaka and
Takeda 2011, 220]
Q28. Patients here actually fall into categories. On the one hand very well informed
patients who want to know everything… And then the other extreme who are extremely
frightened, don’t want to know [Consultant physician, UK; Will, Armstrong, and
Marteau 2010, 913]
Q29. And you might say that … what you notice when you have [counselling sessions for]
such large families is that people have (…) made up their minds of whether they have
inherited it [the known gene fault] prior to their appointments. [Genetic counsellor,
Norway; Aasen and Skolbekken 2014, 377]
Q30. Sometimes they [African American women] just don’t want to know or are not ready
to know yet … but sometimes it’s really the family that doesn’t want to know so they
discourage it [getting tested]. [Genetic counsellor, USA; Graves et al. 2011, 684]
Q31. Now when the media [come] out with a lot of publicity and some people aren’t
particularly eligible or the risk isn’t as high as they think it is, [they] come in and ask
me about it. We just kind of go over it. Like, your risk isn’t particularly high. You can
see [genetic testing programs] if you want, but your risk isn’t as high as you think it is.
[Physician, Canada; Bottorff et al. 2000, 1453]
Q32. I get a lot of people who have got this stuff off the Internet who want to know,
‘Where can I get genetic screening? Am I going to get cancer? [Family physician,
Canada, Carroll et al. 2003, 48]
Q33. We have some Caucasian patients that clearly don’t need to be tested and are
clamoring for it, and it’s… the opposite in the African American community. [Breast
surgeon, USA; Graves et al. 2011, 680]
Q34. It can make choices at times when they are otherwise healthy difﬁcult, and it could
be confounded, for example, if they don’t have good medical care or insurance.
[Medical oncologist, USA; Graves et al. 2011, 678]
Subtheme 2c. Facilitating understanding
Q35. I think people need to hear the information in several different ways, so increased
risks, you know, decreased risks, no risk or population risk of breast cancer, that can
mean very different things to people. [Genetic counsellor, USA; Overby et al. 2013,
244]
Q36. In all cases, we give support materials for consultation after the visit to the centre, for
calm reading … when we are discussing more complex information I like to use
metaphors, so the comprehension of genetic information will be facilitated. [Resident of
medical genetics, Portugal; Paneque et al. 2014, 4]
Q37. For polycystic kidney disease we would need to obviously have supplemental
education pamphlets you can hand out to people. Give them easy to read information
that they can take home with them. [Nurse, Canada; Cox and Starzomski 2004, 147]
Theme 3. Consequences of genetic risk information
Subtheme 3a. Anxiety
Q38. It’s like why are we doing a test that raises anxiety and increases the cost of care?
[Provider, USA; Birmingham et al. 2013, 8]
Q39. People often get distressed when they realize that close relatives may also be at risk,
especially younger descendants under 18 or in their twenties. Positive results in such
cases are the most dramatic. [Genetic HCP; Portugal; Mendes, Sousa, and Paneque
2013, 777]
(Continued)
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Q40. Sometimes we’re actually going to increase people’s anxiety… and sometimes we’re
going to alleviate anxiety, but I mean part of our role is to deﬁne those risks for them
and help them understand what’s going on … to get more information. Getting the
genetic information is part of your information-gathering process, and if you don’t do
that, then you’re not using all the tools you have. [Family physician, Canada; Carroll
et al. 2003, 49–50]
Q41. I will always try to … I don’t know if it’s always [the] right [strategy] but … at least
at the beginning [of the consultation], then I always try … not to frighten them. [Genetic
counsellor, Norway; Aasen and Skolbekken 2014, 380]
Q42. We do [evaluate when or if psychosocial support is needed] … somehow we try to
manage by ourselves the difﬁcult moments in the consultation but it is not enough
because there is no psychologist in the service! [Genetics HCP, Portugal; Mendes,
Sousa, and Paneque 2013, 776]
Q43. Well, certainly in terms of explaining basic genetics, I can explain that to anyone
probably in my sleep, but if something unusual shows up on a genetic test, that is the
beneﬁt of working in a multidisciplinary team – if you don’t know the answer maybe
someone else does. [Nurse, Canada; Bottorff et al. 2005, 104]
Q44. I am not trained in counselling, and I rely on members of my team to ﬁll that vital
role. [Clinical geneticist, Australia; Lobb et al. 2001, 194]
Q45. Psychosocial issues are linked to genetic counseling … but I need to separate what is
not my expertise and guarantee a good articulation with the consultation meant for those
issues with our psychologist. [Medical geneticist, Portugal; Paneque et al. 2014, 5]
Q46. Sometimes I refer because the patient is extremely anxious. [General practitioner,
UK; Al-Habsi et al. 2008, 755]
Q47. It empowers people to ﬁnd out [their risk of a BRCA1/2 mutation] and alleviate
fears. [Obstetrician/gynaecologist, USA; Graves et al. 2011, 678]
Subtheme 3b. Discrimination and stigmatization
Q48. I remember one [patient] who told me ‘I don’t want anybody to peek into my private
life.’ [Another patient] said, ‘I think if I ﬁnd out I have BRCA1 then … I won’t get
health insurance because of discrimination’. [Medical oncologist, USA; Graves et al.
2011, 678]
Q49. I think the potential for discrimination down the road may be substantial. [Genetic
counsellor, USA; Pfeffer, Veach, and LeRoy 2003, 426]
Q50. (Genetic testing) potentially opens cans of worms as far as the daughter’s insurability
is concerned … knowing that she’s got the genetic predisposition to cancer doesn’t
change anything. [Gynaecologist, Australia; Tan and Fitzgerald 2014, 4]
Q51. If genetic information is included in a patient’s electronic medical record, we are
concerned over potential information leakage. [Breast specialist, Japan; Komatsu and
Yagasaki 2014, 42]
Q52. African American patients oftentimes tend to be more suspicious about [genetic
testing] … because they’re so used to being pointed out all the time. And maybe they
feel it’s another way of [labeling them]. [Medical oncologist, USA; Graves et al. 2011,
680]
Q53. I believe this can be very therapeutic as in many cases these families feel isolated
and stigmatised. [Genetics HCP, Portugal; Mendes, Paneque, and Sousa 2012, 314]
Subtheme 3c. Impact on family
Q54. Within genetics we are very aware of the family issues of genetic testing and we
often feel that, you know, it can be described as being unethical to do genetic tests
without consideration of the impact on other members of the family. [Genetics specialist,
UK; Harvey 2011, 314]
Q55. If we ﬁnd a mutation in one of our patients, we want her relatives to take the test as
soon as possible. But it is a very sensitive issue because each family’s situation is
different [Genetic counsellor, Japan; Komatsu and Yagasaki 2014, 41]
Q56. Many of them [oncologists] are still stuck in the mode of treating the diseased
person, not the family. The vast majority are still in that mode, because that is how
they’ve been trained. In order to treat the person with the disease, they don’t really deal
(Continued)
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with the whole family who is worried about having the disease. [Clinical geneticist,
Canada; Miller, Giacomini, and Ahern 2008, 155]
Q57. Some patients do not want their families to know about their conditions. It is not
easy to give the family members a telephone call [Breast specialist, Japan; Komatsu and
Yagasaki 2014, 41]
Q58. We feel sometimes is complicated for people to get in touch with them [potentially
at-risk relatives] and tell them [they might be at-risk]. Sometimes conﬂicts prevent this
happening, or people don’t see each other often, or because they fear a bad reaction.
[Genetics HCP, Portugal; Mendes, Sousa, and Paneque 2013, 777]
Theme 4. Responsibility for genetic risk information
Subtheme 4a. Genetic risk as a burden
Q59. People feel so guilty for transmitting or potentially transmitting a genetic disease
which, when you think about it is, I mean they shouldn’t. [Nephrologist, Canada; Cox
and Starzomski 2004, 149]
Q60. If the mother has the gene, she feels like she might have tainted her offspring. If a
sister doesn’t have the gene and her sister does, then the sister that doesn’t have it might
feel guilty. [Breast surgeon, USA; Graves et al. 2011, 681]
Q61. For a woman who has a strong family history she may learn that she doesn’t carry a
familial genetic risk factor so she may be relieved from having to make various medical
decisions. Sometimes gaining additional information about risk can be reassuring even if
people learn that they’re at increased risk because at least they have information.
[Genetic Counsellor, USA; Graves et al. 2011, 681]
Q62. [I could tell them that their cholesterol was] different from Joe Public’s cholesterol
which may well be raised because of a bad diet or something else. [Consultant
physician, UK; Will, Armstrong, and Marteau 2010, 914]
Subtheme 4b. Responsibility to act on risk information
Q63. In some situations, [it’s] a disadvantage that the ﬁrst person to be tested in the family
gets the job of having to spread the information to everyone and that can be somewhat
of a burden for people. [Genetic counsellor, USA; Graves et al. 2011, 682]
Q64. It is up to the patient to decide whether to inform her relatives of the results of the
genetic test. [Breast specialist, Japan; Komatsu and Yagasaki 2014, 42]
Q65. Because potentially you could really be, you know, sort of adding to somebody’s
burden by raising those issues if, well one, they hadn’t thought about it and then they
were raised and they thought, ‘Oh my goodness I really need to do something about
this’ or, ‘I haven’t been doing this and this, you know, it’s going to contribute to my
disease risk’ and all of that sort of thing. [Genetic counsellor, Australia; Rees et al.
2006, 101]
Q66. Secondly, you know that probably some people are having surgery unnecessarily, and
thirdly … you would feel much happier about doing the screening measures or
prophylactic surgery measure that were quite extreme, if this level of certainty was much
higher [Oncologist, UK; Kenen et al. 2011, 5]
Q67. It’s a two-way-street. It’s our responsibility to make sure that families know that
nephrology is there in terms of long-term management and care issues [Geneticist,
Canada; Cox and Starzomski 2004, 153]
Q68. Even if the counselling is done in what is now secondary care, patients will still
come back to us with their letter and ask to have it interpreted. … it will always end up
back with us. … the main pressures for us to take on counselling is going to come from
the patients because if a patient is sitting in front of you and wants an answer, you feel
obliged to do your best to supply what they need. [General practitioner, Wales; Elwyn,
Iredale, and Gray 2002, 69]
Q69. The follow-up should still be a physician-based thing. So I don’t really have a
problem with the clinics that do the genetic counselling and then send the patient to
whoever would be doing the screening [Genetic counsellor, Canada; Miller, Giacomini,
and Ahern 2008, 157]
(Continued)
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was described as problematic, and likely to lead to ‘dilemma in interpretation’ that
is at odds with the security associated with notions of evidence-based practice and
professional expertise (Birmingham et al. 2003; Carroll et al. 2003; Miller, Giaco-
mini, and Ahern 2008; Kenen et al. 2011).
If you’re going to do something which has a profound signiﬁcance, you’ve got to be
damn sure of the validity of your advice according to the results of that test. And I
don’t think we’re in that position right now. [Family physician, Canada; Carroll et al.
2003, 49]
The lack of perceived added value of genetic information to medical practice was
described in relation to the current practice of the HCPs (Will, Armstrong, and Mar-
teau 2010; Harvey 2011). There is, perhaps, an underlying assumption that current
service provision should be viewed as appropriate and sufﬁcient.
Because at the moment I am looking at risks anyway, just normal family history, and if
someone has a strong family history I will be emphasizing it more anyway. So yes, that
would be just another one. You know, it would just be another issue. [General practi-
tioner, UK; Harvey 2011, 319]
Furthermore, some HCPs emphasised that the provision of genetic risk information
was not always accompanied by effective additional intervention or treatment and so
had limited clinical utility (Cox and Starzomski 2004; Stermer et al. 2004; Harvey
2011; Paneque et al. 2014). We do know that there are some families in which there is
deﬁnitely a genetic component. I think unfortunately anyway the treatment is the same,
it doesn’t change our treatment. [Diabetologist, UK; Harvey 2011, 317]
Inactionable genetic information was sometimes associated with a desire to protect
patients from unnecessary medicalization (Stermer et al. 2014) or fear (Cox and
Starzomski 2004).
We don’t want to obsess and medicalise our patients when we have quite a lot of suspi-
cion that there is not going to be much that can be offered by the experts to reassure
them. [General practitioner, UK; Stermer et al. 2004, 50]
Subtheme 4c. Non-directive approach
Q70. I think as geneticists we can say, you know, these are the percentages, we don’t
know … and it’s your decision in the end, so I think in some ways we’re not taking
such a responsibility. I’m sure that surgeons must feel more uneasy than the geneticists.
[Oncologist, UK; Kenen et al. 2011, 9]
Q71. I usually say I can’t guarantee this information won’t be used against them. [Genetic
counsellor, USA; Pfeffer, Veach, and LeRoy 2003, 426]
Q72. We should adopt approaches beyond the medical- traditionalist model [in genetic
counselling] because it is very paternalistic and therefore very difﬁcult to apply
straightforwardly in genetics because we deal with predictive territories. [Genetic HCP,
Portugal; Mendes, Sousa, and Paneque 2013, 775]
Q73. And the other thing I emphasized was that if you knew early that you have the
disease it will become a decision. You have a choice of whether you want children. And
that I tend to shy away from. I just explain to them the chances, not really telling them
exactly what to do because I believe that is a very personal thing. [Nephrologist,
Canada; Cox and Starzomski 2004, 149–150]
Q74. We follow a purely clinical model based on risk measures after collecting the family
history and evaluate if the genetic test is pertinent, and then it is the counselee who will
decide! It is a medical consultation and our role is merely to give correct information
and refer to surveillance or risk reduction options if appropriate. [Genetics HCP,
Portugal; Mendes, Sousa, and Paneque 2013, 775]
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1b. Use of genetic testing in current and future practice (T3; Q11–14)
HCPs were uncomfortable with the speed with which genetic technology has
advanced, in the light of their reservations about the clinical utility of genetic risk
information. This concern was emphasized by the emotive language that was fre-
quently used in this context. HCPs were wary of potential consequences and impli-
cations of genetic test results, which may outweigh any clinical beneﬁt and which
may be overlooked in the ‘overwhelming’ pervasive trend towards genetic medicine
(Carroll et al. 2003; Cox and Starzomski 2004; Kenen et al. 2011).
The frustrating thing is all these tests become available so quickly and you’re swept up
into doing them or people are coming in and asking for certain things, and … you
don’t necessarily realize all the consequences at that point. You’re being swept along
in this wave of newer technology… It’s really overwhelming. It’s hard to know if
you’re doing good by ordering these tests. [Family physician, Canada; Carroll et al.
2003, 49]
Although many HCPs referred to an inevitable future increase in the role for genetic
testing (Elwyn, Iredale, and Gray 2002; Carroll et al. 2003; Cox and Starzomski
2004; Iredale, Jones et al. 2005; Iredale, Elwyn et al. 2007; Al-Habsi et al. 2008;
Miller, Giacomini, and Ahern 2008; Martin, Currie, and Finn 2009; Kenen et al.
2011), this trend was associated with feeling under ‘pressure’ to respond to an
increased demand for genetic services, and with feeling unable to respond without
specialist support.
I think cancer genetics will, I think all predictive genetics will end up becoming part of
general health care. We have, I just counted, I think 30 clinical geneticists in Ontario.
Probably about 100 across the country. We cannot possibly see all these people. We
just can’t. So I think what has to happen is that the geneticists will end up in a consul-
tative role and we will kind of get things going. [Clinical geneticist, Canada; Miller,
Giacomini, and Ahern 2008, 156]
Whilst the translation of genetic technology was described as a future prospect, cur-
rent provision of predictive genetic testing was described as reactive by some HCPs,
responding to self-selected patient’s, rather than being under the direction of the
HCP (Elwyn, Iredale, and Gray 2002; Cox and Starzomski 2004; Al-Habsi et al.
2008; Martin, Currie, and Finn 2009; Paneque et al. 2014).
Some people come and say ‘Can I be referred to ﬁnd out more?’ And that’s what they
want. So then it’s quite hard to say no. [General practitioner, UK; Al-Habsi et al. 2008,
755]
In this situation, the risk information provided is sought out and valued by the
patient rather than the provider. This is, perhaps at odds with traditional notions of
professional authority and expertise.
1c. Impact on health-related behaviour (T3; Q15–18)
A few HCPs stated that genetic risk information relating to multifactorial diseases
could have a positive impact on patients’ health-related behaviour. On the one hand,
such information was described as potentially ‘empowering’, by encouraging indi-
viduals to make appropriate changes to their lifestyle (Cox and Starzomski 2004;
Rees et al. 2006; Will, Armstrong, and Marteau 2010; Yamanaka and Takeda 2011),
whilst on the other hand this information was conceived of as potentially useful to
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align patient behaviour towards ‘compliance’ with medical advice (Birmingham
et al. 2003; Graves et al. 2011).
I guess Polycystic is a little different, because there are things you can do, there’s even
diet, you can take control of your diet. And there is a sense that you’re doing some-
thing, right? [Social worker, Canada; Cox and Starzomski 2004, 145]
It might actually, if a patient sees the increased risk, increase their compliance as far as
coming in for regular exams or at least being willing to get the digital rectal exam.
[Provider, USA; Birmingham et al. 2003, 8]
However, many were pessimistic about their inﬂuence on their patients’ lifestyle
choices, and felt that a positive effect of genetic risk information on patients’ health
behaviours was unlikely (Birmingham et al. 2003; Rees et al. 2006). Some felt that
an emphasis on genetic risk factors could even have a negative behavioural effect
by detracting from the importance of lifestyle-related risk factors (Birmingham et al.
2003; Iredale et al. 2007; Yamanaka and Takeda 2011).
You can talk until you’re blue in the face about all these things being a good thing but
actually, these kind of health behaviors are very difﬁcult if people aren’t doing them
already and which is why the world is becoming a fatter place. Because people don’t
do the things they’re meant to be doing. So I think although I think it’s my role to pro-
mote these things and we’ll talk about it, I feel a bit nihilistic about the fact that I don’t
think people are going to change. Most people are not going to change their behaviors.
[Medical specialist, Australia; Rees et al. 2006, 101]
These accounts reﬂect a sense of powerlessness and frustration on the part of provi-
ders in relation to their inability to effect positive behavioural change by their
patients, both in response to genetic information and more generally. As patients
often exercise their autonomous right to choose not to adhere to medical advice, the
HCPs felt ‘nihilistic’ about the effectiveness of the information they provide.
Theme 2: Understanding of genetic risk information (T3; Q19–25)
This theme describes HCPs’ views on patients’ and HCPs’ abilities to understand
and make appropriate use of genetic risk information, and how this relates to the
demand for and the delivery of such information.
2a. Assessment of understanding
Several HCPs noted that patients often do not understand the nature of genetic risk
information, and that patients do not appreciate the uncertainty associated with risk
information (Bottorff et al. 2000; Lobb et al. 2001; Elwyn, Iredale, and Gray 2002;
Cox and Starzomski 2004; Graves et al. 2011; Kenen et al. 2011; Overby et al.
2013; Aasen and Skolbekken 2014).
Most women don’t know. They kind of come up with this statement of, ‘Okay, I want
to know if I carry the gene or not.’ They have no idea what the implications are, what
it means, what the risks are. I mean, it is sort of like a ‘yes or no’ test they are looking
for. [Physician, Canada; Bottorff et al. 2000, 1453]
A level of uncertainty surrounding genetic information was also felt by HCPs. Some
HCPs expressed reservations about their own understanding and conﬁdence in
genetic risk assessment (Elwyn, Iredale, and Gray 2002; Carroll et al. 2003;
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Al-Habsi et al. 2008; Graves et al. 2011; Kenen et al. 2011; Birmingham et al.
2013; Mendes, Sousa, and Paneque 2013; Tan and Fitzgerald 2014).
And sometimes I have to sit and think about … [the results] because like you said, just
in that little discussion we had, we were all looking at it [statistical computation of
risk] and going, now wait a minute, what is this and what is this? [Provider, USA;
Birmingham et al. 2003, 7]
However, despite reservations about their own knowledge, HCPs clearly saw their
own understanding of genetic risk as being qualitatively different, and superior to,
the understanding of members of the public. Professional understanding is described
in terms of precise, quantitative estimates, whereas public understanding is described
in vague, experiential terms (Overby et al. 2013).
I don’t think when people are thinking about their risk, they’re thinking about them in
numbers the way we are, so as geneticists, we’re thinking about your risk as 15 vs.
10%, but for the average woman, they might just be feeling like, ‘Yeah, my mom and
sister got breast cancer; it’s probably going to happen to me too’. [Genetic counsellor,
USA; Overby et al. 2013, 245]
HCPs described their role as the process of making a complex evaluation of the
multiple factors that could inﬂuence the understanding and beliefs of individual
patients, in order to ascertain their needs (Lobb et al. 2001).
I deﬁne genetic counselling as recognizing and exploring issues that are relevant for a
particular family member. For example, previous family history, what happened, how
that has affected the client’s view of breast cancer, what the outcomes have been for
the family, what position/age the person was when she (ﬁrst) became aware of family
history and the impact that has had on her (e.g. mother diagnosed with breast cancer
when going through adolescence). [Genetic counsellor, Australia; Lobb et al. 2001,
190]
The professional role was sometimes described as being complicated by difﬁculty in
eliciting reliable information from patients about their family history (Cox and Star-
zomski 2004; Iredale et al. 2005; Al-Habsi et al. 2008; Graves et al. 2011; Overby
et al. 2013; Tan and Fitzgerald 2014).
There are patients here I saw three years ago with nothing particular in their family his-
tory and they present three years later with two or three family members with breast
cancer. [Nurse, Wales; Iredale et al. 2005, 201]
2b. Determinants of understanding (T3; Q26–34)
Patients’ understanding of genetic risk and their reactions to risk information were
described as being inﬂuenced by a wide range of cognitive processes and social fac-
tors, including patients’ beliefs, expectations and motivations. HCPs described mak-
ing judgements about how these factors affect the level of understanding.
Furthermore, depending on the level of understanding and motives for undergoing
testing HCPs would modify their approach to match the perceived needs of the
patient (Lobb et al. 2001; Pfeffer, Veach, and LeRoy 2003; Cox and Starzomski
2004; Stermer et al. 2004; Rees et al. 2006; Will, Armstrong, and Marteau 2010;
Yamanaka and Takeda 2011; Mendes, Paneque, and Sousa 2012; Mendes, Sousa,
and Paneque 2013; Overby et al. 2013; Aasen and Skolbekken 2014; Paneque et al.
2014).
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You need to change your approach according to the sensibilities of your patients so as
to assure positive effects of the test results. [Diabetologist, Japan; Yamanaka and
Takeda 2011, 220]
HCPs referred to variability in patients’ desire to know their disease risk status,
which was associated with patients’ level of understanding and knowledge. (Will,
Armstrong, and Marteau 2010; Graves et al. 2011; Yamanaka and Takeda 2011;
Komatsu and Yagasaki 2014; Tan and Fitzgerald 2014).
Patients here actually fall into categories. On the one hand very well informed patients
who want to know everything … And then the other extreme who are extremely fright-
ened, don’t want to know [Consultant physician, UK; Will, Armstrong, and Marteau
2010, 913].
Family background, particularly personal experience of a disease, and cultural back-
ground were frequently cited as important determinants of a patient’s understanding
of and responses to genetic risk (Lobb et al. 2001; Carroll et al. 2003; Cox and Star-
zomski 2004; Graves et al. 2011; Overby et al. 2013; Aasen and Skolbekken 2014;
Komatsu and Yagasaki 2014; Tan and Fitzgerald 2014).
And you might say that … what you notice when you have [counselling sessions for]
such large families is that people have (…) made up their minds of whether they have
inherited it [the known gene fault] prior to their appointments. [Genetic counsellor,
Norway; Aasen and Skolbekken 2014, 377]
Sociocultural inﬂuences (Cox and Starzomski 2004; Graves et al. 2011; Mendes,
Sousa, and Paneque 2013) and media inﬂuences (Bottorff et al. 2000; Elwyn, Ire-
dale, and Gray 2002; Carroll et al. 2003; Kenen et al. 2011) were cited by HCPs in
several of the articles included in this analysis as important determinants of public
perceptions of risk.
Now when the media [come] out with a lot of publicity and some people aren’t partic-
ularly eligible or the risk isn’t as high as they think it is, [they] come in and ask me
about it. We just kind of go over it. Like, your risk isn’t particularly high. You can see
[genetic testing programs] if you want, but your risk isn’t as high as you think it is.
[Physician, Canada; Bottorff et al. 2000, 1453]
Cultural differences in risk appraisal meant that some groups were less likely to par-
ticipate in predictive testing than others, and that there was a misalignment between
need for and demand for genetic testing.
We have some Caucasian patients that clearly don’t need to be tested and are clamor-
ing for it, and it’s … the opposite in the African American community. [Breast sur-
geon, USA; Graves et al. 2011, 680]
Many HCPs made reference to social inequalities not only in demand for, but also
in access to genetic testing services (Elwyn, Iredale, and Gray 2002; Pfeffer, Veach,
and LeRoy 2003; Iredale et al. 2007; Martin, Currie, and Finn 2009; Graves et al.
2011; Mendes, Paneque, and Sousa 2012; Mendes, Sousa, and Paneque 2013).
It can make choices at times when they are otherwise healthy difﬁcult, and it could be
confounded, for example, if they don’t have good medical care or insurance. [Medical
oncologist, USA; Graves et al. 2011, 678]
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2c. Facilitating understanding (T3; Q35–37)
The approach taken by HCPs to the provision of genetic risk information was asso-
ciated with their judgement of individual patients’ needs and capabilities. The
importance of communicating risk information in a variety of formats appropriate
for the needs of the patient was noted by several HCPs, and some described using
approaches such as the use of metaphors (Lobb et al. 2001; Stermer et al. 2004;
Overby et al. 2013; Paneque et al. 2014).
I think people need to hear the information in several different ways, so increased
risks, you know, decreased risks, no risk or population risk of breast cancer, that can
mean very different things to people. [Genetic counsellor, USA; Overby et al. 2013,
244]
The use of supplementary sources of information was often mentioned, especially
accessible informational resources that patients could take away and read in their
own time (Elwyn, Iredale, and Gray 2002; Pfeffer, Veach, and LeRoy 2003; Cox
and Starzomski 2004; Rees et al. 2006; Mendes, Sousa, and Paneque 2013; Paneque
et al. 2014; Tan and Fitzgerald 2014).
For polycystic kidney disease we would need to obviously have supplemental educa-
tion pamphlets you can hand out to people. Give them easy to read information that
they can take home with them. [Nurse, Canada; Cox and Starzomski 2004, 147]
Other suggestions for effective communication to enhance patients’ understanding
of genetic risk included the acknowledgement of speciﬁc cultural beliefs and prac-
tices (Graves et al. 2011), helping patients to express themselves (Mendes, Sousa,
and Paneque 2013) and honest involvement of patients in the associated uncertainty
(Kenen et al. 2011).
Theme 3: Consequences of genetic risk information
This theme describes HCPs concerns about the potential negative psychological and
social consequences associated with genetic risk information, both for patients and
for their families. These include the potential for anxiety, discrimination and
stigmatization.
3a. Anxiety (T3; Q38–47)
The potential for knowledge of genetic risk to cause anxiety was a recurring theme.
In some cases, the distress to patients caused HCPs to question whether doing the
tests was worthwhile (Lobb et al. 2001; Cox and Starzomski 2004; Al-Habsi et al.
2008; Graves et al. 2011; Mendes, Paneque, and Sousa 2012; Walsh et al. 2012;
Birmingham et al. 2013; Mendes, Sousa, and Paneque 2013; Tan and Fitzgerald
2014).
It’s like why are we doing a test that raises anxiety and increases the cost of care?
[Provider, USA; Birmingham et al. 2013, 8]
HCPs acknowledged that anxiety may be precipitated by awareness of the
signiﬁcance of genetic risk information for other family members.
People often get distressed when they realize that close relatives may also be at risk,
especially younger descendants under 18 or in their twenties. Positive results in such
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cases are the most dramatic. [Genetic HCP; Portugal; Mendes, Sousa, and Paneque
2013, 777]
The role of the HCP in the management of anxiety associated with genetic risk and
the provision of psychosocial support to patients were frequently referred to (Bot-
torff et al. 2000; Elwyn, Iredale, and Gray 2002; Carroll et al. 2003; Cox and Star-
zomski 2004; Birmingham et al. 2013; Mendes, Sousa, and Paneque 2013; Aasen
and Skolbekken 2014). The desire to protect patients from anxiety is balanced
against the desire to equip patients with accurate knowledge to facilitate appropriate
decision-making.
Sometimes we’re actually going to increase people’s anxiety… and sometimes we’re
going to alleviate anxiety, but I mean part of our role is to deﬁne those risks for them
and help them understand what’s going on … to get more information. Getting the
genetic information is part of your information-gathering process, and if you don’t do
that, then you’re not using all the tools you have. [Family physician, Canada; Carroll
et al. 2003, 49–50]
Some HCPs described feeling uncertain about the best approach to manage patients’
anxiety and expressed a desire to protect people from fear. Some stated that special-
ist help was needed to counsel distressed patients (Mendes, Sousa, and Paneque
2013; Aasen and Skolbekken 2014).
We do [evaluate when or if psychosocial support is needed] … somehow we try to
manage by ourselves the difﬁcult moments in the consultation but it is not enough
because there is no psychologist in the service! [Genetics HCP, Portugal; Mendes,
Sousa, and Paneque 2013, 776]
The need for multidisciplinary support in the delivery of genetic risk information
was often acknowledged, with many HCPs feeling that they were not equipped with
the necessary specialist skills to support their patients (Lobb et al. 2001; Carroll
et al. 2003; Bottorff et al. 2005; Mendes, Paneque, and Sousa 2012; Mendes, Sousa,
and Paneque 2013; Paneque et al. 2014).
I am not trained in counselling, and I rely on members of my team to ﬁll that vital
role. [Clinical geneticist, Australia; Lobb et al. 2001, 194]
In some instances, anxiety was referred to as a reason to engage in genetic testing
(Lobb et al. 2001; Elwyn, Iredale, and Gray 2002; Al-Habsi et al. 2008; Aasen and
Skolbekken 2014; Paneque et al. 2014).
Sometimes I refer because the patient is extremely anxious. [General practitioner, UK;
Al-Habsi et al. 2008, 755]
Some HCPs mentioned the potential for anxiety to be relieved by information about
genetic risk and described this as an empowering experience (Carroll et al. 2003;
Cox and Starzomski 2004; Graves et al. 2011).
It empowers people to ﬁnd out [their risk of a BRCA1/2 mutation] and alleviate fears.
[Obstetrician/gynaecologist, USA; Graves et al. 2011, 678]
3b. Discrimination and stigmatization (T3; Q48–53)
The potential for genetic risk information to be used to discriminate against patients
was a recurring concept (Pfeffer, Veach, and LeRoy 2003; Cox and Starzomski
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2004; Al-Habsi et al. 2008; Graves et al. 2011; Birmingham et al. 2013; Komatsu
and Yagasaki 2014; Tan and Fitzgerald 2014).
I think the potential for discrimination down the road may be substantial. [Genetic
counsellor, USA; Pfeffer, Veach, and LeRoy 2003, 426]
Whilst healthcare providers showed awareness and concern in relation to the poten-
tial for discrimination, only rarely was this associated with discussion of their own
role in the management of this issue.
If genetic information is included in a patient’s electronic medical record, we are con-
cerned over potential information leakage. [Breast specialist, Japan; Komatsu and
Yagasaki 2014, 42]
HCPs also referred to the potential for patients to feel stigmatized or labelled as a
result of receiving information about their genetic risk status (Cox and Starzomski
2004; Graves et al. 2011; Mendes, Paneque, and Sousa 2012).
African American patients oftentimes tend to be more suspicious about [genetic test-
ing] … because they’re so used to being pointed out all the time. And maybe they feel
it’s another way of [labeling them]. [Medical oncologist, USA; Graves et al. 2011,
680]
These statements show an awareness that having an inherited predisposition for a
disease can have an important and potentially negative impact on the identity of
individuals and families, and how they are perceived by society. In this sense, being
‘at risk’ of a disease has the potential to separate the individual and their family
from others, and to change the way that others relate to them.
3c. Impact on family (T3; Q54–58)
The fact that genetic risk information impacts on the family, and not just the individ-
ual patient was mentioned across studies (Lobb et al. 2001; Carroll et al. 2003;
Miller, Giacomini, and Ahern 2008; Graves et al. 2011; Harvey 2011; Walsh et al.
2012; Mendes, Sousa, and Paneque 2013; Komatsu and Yagasaki 2014; Paneque
et al. 2014; Tan and Fitzgerald 2014).
Within genetics we are very aware of the family issues of genetic testing and we often
feel that, you know, it can be described as being unethical to do genetic tests without
consideration of the impact on other members of the family. [Genetics specialist, UK;
Harvey 2011, 314]
The need for HCPs to be aware of this wider impact of genetic information, and to
respond appropriately, was described as challenging for traditional and existing mod-
els of service provision.
Many of them [oncologists] are still stuck in the mode of treating the diseased person,
not the family. The vast majority are still in that mode, because that is how they’ve
been trained. In order to treat the person with the disease, they don’t really deal with
the whole family who is worried about having the disease. [Clinical geneticist, Canada;
Miller, Giacomini, and Ahern 2008, 155]
HCPs acknowledged that individuals may engage with genetic testing for the sake
of their family (Carroll et al. 2003; Will, Armstrong, and Marteau 2010; Graves
et al. 2011; Tan and Fitzgerald 2014), or may decide that they do not wish to share
their genetic risk status with others (Carroll et al. 2003; Graves et al. 2011; Mendes,
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Sousa, and Paneque 2013; Komatsu and Yagasaki 2014), or they may have difﬁculty
accessing or communicating about disease risk with some family members (Mendes,
Sousa, and Paneque 2013).
We feel sometimes is complicated for people to get in touch with them [potentially at-
risk relatives] and tell them [they might be at-risk]. Sometimes conﬂicts prevent this
happening, or people don’t see each other often, or because they fear a bad reaction.
[Genetics HCP, Portugal; Mendes, Sousa, and Paneque 2013, 777]
Although HCPs recognized the need to ‘treat the family’ rather than the individual
in this context, the familial transmission of information about genetic risk is outside
the sphere of inﬂuence of the professional, and dependent on the views of individual
patients, and their autonomous choice to share, or not to share, potentially distress-
ing, sensitive or private information. This may be particularly problematic when risk
information has preventive or reproductive implications for relatives. Providing pro-
fessional support and intervention for all who may be affected by genetic informa-
tion may not be possible for current methods of service provision.
Theme 4: Responsibility for genetic risk information
This theme includes statements where information about genetic risk was associated
with a sense of responsibility.1 These include feelings of guilt on the part of those
found to be at risk of the disease, and thus having potential to pass on this increased
risk to their offspring; responsibility to share information about disease risk with
others who may be affected; responsibility to take preventive action to reduce risk;
and HCPs’ responsibility to treat and support patients.
4a. Genetic risk as a burden (T3; Q59–62)
Genetic risk was frequently referred to as a burden (Rees et al. 2006; Graves et al.
2011; Kenen et al. 2011; Mendes, Paneque, and Sousa 2012; Aasen and Skolbekken
2014; Paneque et al. 2014) or associated with feelings of guilt (Lobb et al. 2001;
Carroll et al. 2003; Cox and Starzomski 2004; Will, Armstrong, and Marteau 2010;
Graves et al. 2011). HCPs described patients feeling guilty for transmitting a herita-
ble disease, or for being unaffected by a disease when other members of the family
were affected.
If the mother has the gene, she feels like she might have tainted her offspring. If a sis-
ter doesn’t have the gene and her sister does, then the sister that doesn’t have it might
feel guilty. [Breast surgeon, USA; Graves et al. 2011, 681]
Genetic risk information was also described as potentially relieving responsibility by
reducing a patient’s risk status (Graves et al. 2011), or by accounting for disease sta-
tus and detracting from responsibility for lifestyle choices (Will, Armstrong, and
Marteau 2010).
For a woman who has a strong family history she may learn that she doesn’t carry a
familial genetic risk factor so she may be relieved from having to make various medi-
cal decisions. Sometimes gaining additional information about risk can be reassuring
even if people learn that they’re at increased risk because at least they have informa-
tion. [Genetic Counsellor, USA; Graves et al. 2011, 681]
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[I could tell them that their cholesterol was] different from Joe Public’s cholesterol
which may well be raised because of a bad diet or something else. [Consultant physi-
cian, UK; Will, Armstrong, and Marteau 2010, 914]
4b. Responsibility to act on risk information (T3; Q63–69)
Genetic risk was associated with a responsibility to decide whether or not to share
risk information with other family members who may also be affected (Carroll et al.
2003; Graves et al. 2011; Komatsu and Yagasaki 2014).
In some situations, [it’s] a disadvantage that the ﬁrst person to be tested in the family
gets the job of having to spread the information to everyone and that can be somewhat
of a burden for people. [Genetic counsellor, USA; Graves et al. 2011, 682]
It is up to the patient to decide whether to inform her relatives of the results of the
genetic test. [Breast specialist, Japan; Komatsu and Yagasaki 2014, 42]
Genetic risk was also associated with a responsibility to respond in other ways, such
as to make lifestyle changes (Rees et al. 2006), or to decide whether or not to have
children (Cox and Starzomski 2004) or whether or not to undergo prophylactic sur-
gery (Graves et al. 2011; Kenen et al. 2011).
Because potentially you could really be, you know, sort of adding to somebody’s bur-
den by raising those issues if, well one, they hadn’t thought about it and then they
were raised and they thought, ‘Oh my goodness I really need to do something about
this’ or, ‘I haven’t been doing this and this, you know, it’s going to contribute to my
disease risk’ and all of that sort of thing. [Genetic counsellor, Australia; Rees et al.
2006, 101]
Responsibility was also frequently referred to with reference to the need for HCPs
to provide services and support following genetic testing (Elwyn, Iredale, and Gray
2002; Cox and Starzomski 2004; Miller, Giacomini, and Ahern 2008; Graves et al.
2011; Komatsu and Yagasaki 2014; Paneque et al. 2014).
It’s a two-way-street. It’s our responsibility to make sure that families know that
nephrology is there in terms of long-term management and care issues [Geneticist,
Canada; Cox and Starzomski 2004, 153]
4c. Non-directive approach to genetic risk (T3; Q70–79)
HCPs frequently attributed ultimate responsibility to interpret or respond to genetic
risk to their patients (Lobb et al. 2001; Pfeffer, Veach, and LeRoy 2003; Cox and
Starzomski 2004; Kenen et al. 2011; Mendes, Sousa, and Paneque 2013; Overby
et al. 2013; Tan and Fitzgerald 2014) or to other professionals (Kenen et al. 2011;
Birmingham et al. 2013), rather than themselves.
I think as geneticists we can say, you know, these are the percentages, we don’t know
… and it’s your decision in the end, so I think in some ways we’re not taking such a
responsibility. I’m sure that surgeons must feel more uneasy than the geneticists.
[Oncologist, UK; Kenen et al. 2011, 9]
The consensual approach was described as being non-directive, with the role of the
professional being to provide information and support to empower the patient make
informed decisions.
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My job is I guess to provide the information and then the patient can decide what they
want. [Gynaecological oncologist, Australia; Tan and Fitzgerald 2014, 95]
Two articles reported that although the majority of HCPs preferred a non-directive
approach, some would use a directive manner regarding the adoption of health pro-
tective behaviours (Rees et al. 2006), and the recommendation of prophylactic sur-
gery (Kenen et al. 2011).
I certainly talk about smoking if I’ve ascertained earlier on that the woman is a smoker.
I have to admit I do discuss that, you know, in relative detail that they should try and
give up or cut it down as much as they can. [Medical specialist, Australia; Rees et al.
2006, 99]
The non-directive approach adopted by the majority of HCPs in this context is
reﬂected by the fact that the delivery of genetic risk information was often framed in
terms of patient empowerment, control or autonomy (Lobb et al. 2001; Cox and
Starzomski 2004; Rees et al. 2006; Graves et al. 2011; Kenen et al. 2011; Mendes,
Sousa, and Paneque 2013; Paneque et al. 2014).
I think also empowering them to a degree that they can alter their risk and that they
are not a passive player in the whole process, that, you know, that they can actually
impact on reducing their potential risk of developing breast cancer. So I think from
both those perspectives for many women it’s important. [Medical specialist, Australia;
Rees et al. 2006, 101]
Discussion
Previous reviews (Emery et al. 1999; Suther and Goodson 2003; Mikat-Stevens,
Larson, and Tarini 2015) have identiﬁed that HCPs perceive there to be numerous
barriers to the integration of genetic testing and genetic risk communication into
routine clinical practice. The themes developed from this synthesis of the qualitative
literature, with a speciﬁc focus on perceptions of genetic risk, help to contextualize
the persistence of these barriers.
The perceived value of predictive genetic testing was often low with little to add
to existing practice. HCPs were concerned about the rapid introduction of new
genetic technologies without the necessary evidence base to fully inform the use of
these approaches in clinical settings. Patients’ understanding of genetic risk was per-
ceived to be limited, and subject to bias and external inﬂuence. The professional’s
role is conceptualized as an authoritative process of evaluation to untangle these
multiple inﬂuences in order to assess patients’ capabilities and needs and to tailor
their approach accordingly.
Concern about the potential psychological and social impact of genetic risk was
a recurring theme here, and has been identiﬁed as an important barrier to the main-
stream integration of medical genetics in previous reviews (Mikat-Stevens, Larson,
and Tarini 2015). The need to provide comprehensive and often multidisciplinary
support to patients to help them deal with the psychological distress and other nega-
tive consequences that may be associated with predictive genetic testing may be
challenging when resources are stretched. HCPs were aware that the impact of
genetic risk information permeates beyond the individual to families and communi-
ties with ever ﬂuctuating needs and perspectives, and involving social processes
beyond the current scope of inﬂuence of HCPs. Traditional professional–patient
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interactions involve the treatment of an individual, at a particular time. The ﬁndings
of this metasynthesis reﬂect a growing awareness of the limitations of this approach
in the context of predictive genetic testing. This contextualization is challenging for
traditional models of service delivery, but is essential in order to understand patients’
acceptance of, understanding of and responses to genetic risk information, and has
important implications for equality of access to expanding genetic services.
The concept of responsibility was clearly associated with genetic risk informa-
tion. Whilst HCPs accepted responsibility to provide support and care for patients
undergoing predictive genetic testing, responsibility for the resulting information
about risk status and responsibility to act appropriately on the basis of this informa-
tion were mostly attributed to patients, rather than providers. In this context, HCPs
described their role in non-directive terms, as empowering patients to make
informed decisions. However, responsibility for genetic risk for patients is associated
with moral obligation towards others that may conﬂict with their own needs and
interests (Hallowell 1999; Foster et al. 2004). A non-paternalistic, non-directive
stance may have an important absolving function in this context (Salmon and Hall
2003; Schicktanz and Schweda 2012). Ideals of patient autonomy and empowerment
are widely advocated in health policy, and are a valued healthcare outcome
(McAllister et al. 2012), but may also be interpreted here as an appropriate response
to the management of uncertainty (Kenen et al. 2011) and to the challenges of inte-
grating genetic knowledge and technology into clinical practice (Schicktanz 2016).
The construction of the HCPs role as non-directive in this context is at odds with
more paternalistic notions of protecting patients from distress, and of having author-
ity to make judgements about who can, and who cannot understand and make
appropriate use of genetic information, that were identiﬁed in other themes.
Limitations
The qualitative studies reviewed here represent the views of HCPs in the USA,
Canada, Europe, Australia and Japan, and may not be representative of other cultural
perspectives. There are likely to be important cultural differences in responses to
genetic testing (Raz and Schicktanz 2009a, 2009b). The manner in which these dif-
ferences impact on HCPs’ perspectives and practice is an area for future research.
The majority of the studies included in this metasynthesis explored HCPs’ per-
ceptions of predictive genetic testing for hereditary cancers. The results may there-
fore reﬂect issues that are speciﬁc to this disease context. A small number of studies
included related to monogenic, autosomal dominant disorders (e.g. polycystic kidney
disease), where the outcome of predictive genetic testing would be binary, and likely
to be appraised differently than probabilistic estimates of risk for multifactorial con-
ditions. The studies included reﬂect the conditions (mostly inherited cancers) for
which predictive genetic testing is already incorporated into clinical practice. It is
likely that genetic medicine will be applied in this way to a much wider range of
conditions as understanding of genetics continues to grow. Heterogeneity amongst
perceptions of genetic risk relating to different diseases is likely, and further research
is needed to explore variation in perceptions of predictive genetic testing and genetic
risk appraisal between different hereditary disorders.
The review procedures used here focused on pre-symptomatic predictive testing,
and excluded articles that explicitly related to post-symptomatic genetic testing to
conﬁrm diagnosis and/or inform treatment. However, given that the majority of
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articles included in this review related to cancer genetics, it is possible that some of
the extracts used may refer to HCPs’ experiences of genetic testing to predict reoc-
currence of hereditary cancers in those who have already been affected by the dis-
ease.
Conclusions
The perceived resource barriers to the integration of predictive genetic testing into
mainstream clinical practice that have been identiﬁed in both early and recent
reviews may be symptomatic of challenging social and ethical considerations associ-
ated with genetic risk which are not well aligned with current practice. The ﬁndings
of this metasynthesis contribute an in-depth analysis and integration of the qualita-
tive research literature, and help to contextualize the persistence of these barriers, as
they are perceived by health care providers.
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Note
1. For a philosophical account of genetic risk information and responsibility, see the
contribution by Silke Schicktanz in this issue of the Journal of Risk Research.
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